EP0939616A1 - Compositions topiques aqueuses a base d'acide kojique, d'acide salicylique et d'ether glycolique hydrosoluble - Google Patents

Compositions topiques aqueuses a base d'acide kojique, d'acide salicylique et d'ether glycolique hydrosoluble

Info

Publication number
EP0939616A1
EP0939616A1 EP96937713A EP96937713A EP0939616A1 EP 0939616 A1 EP0939616 A1 EP 0939616A1 EP 96937713 A EP96937713 A EP 96937713A EP 96937713 A EP96937713 A EP 96937713A EP 0939616 A1 EP0939616 A1 EP 0939616A1
Authority
EP
European Patent Office
Prior art keywords
composition
skin
weight
water
aqueous topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96937713A
Other languages
German (de)
English (en)
Inventor
Takayoshi Sakoda
Kazumi Toyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP0939616A1 publication Critical patent/EP0939616A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin

Definitions

  • the present invention relates to an aqueous topical compositions such as lotions, toners, and astringents comprising kojic acid, salicylic acid and a water soluble glycol ether which is useful for lightening of mammalian skin.
  • Skin lightening is an important skin care need, especially in the Asian population. This includes overall lightening of basal skin tone and hyperpigmented lesions. It is generally known that conditions which result in defective or missing tyrosinase, an enzyme involved in the formation of melanin, lead to a loss of pigmentation, e.g. albinism. Conversely, it is known that inhibition of tyrosinase leads to skin lightening via inhibition of melanogenesis. See King, R. A. and C. G. Summers, Dermatoloeic Clinics. Vol. 6 pp. 217-227 (1988).
  • Tyrosinase is present within the melanosomes in epidermal melanocytes and catalyzes the formation of melanin from tyrosine. See Goldsmith, L. A., Physiology. Biochemistry, and Molecular Biology of the Skin. Oxford University Press, pp. 873-903 (N.Y. 1991). Binding of an inhibitor to the active site of tyrosinase results in decreased melanin formation. See generally Prota, G. Melanins and Melanogenesis. Academic Press, Inc., (San Diego 1992).
  • any active in any composition especially when used for topical application (whether for pharmaceutical or cosmetic purposes) must be efficacious, bioavailable, stable when exposed to light, air or to the skin. Should the product be unstable, the breakdown products of the active must be innocuous.
  • kojic acid One known tyrosinase inhibitor is kojic acid.
  • Kojic acid has been found to be quite useful for topical skin lightening compositions.
  • kojic acid is quite expensive.
  • kojic acid does not have an exfoliation effect.
  • One solution to add exfoliation effect on kojic acid is the addition of salicylic acid to the topical composition.
  • Salicylic acid is commonly used in topical compositions because of its exfoliation effects. When combined with kojic acid, salicylic acid exfoliates mammalian skin which results in improving removal effect of skin pigmentation.
  • An example of such a topical skin lightening composition is found in Japanese Patent Laid-open (KOKAI) No. 7- 300404.
  • the present invention relates to an aqueous topical composition for skin lightening comprising:
  • composition from about 20% to about 30% by weight of the composition, of a water soluble glycol ether of the general formula: R 1 -0-[(CH2)mO]nH; wherein R 1 is an alkyl of 1 to 6 carbon atoms, m is from about 2 to about 3, and n is from about 1 to about 2; wherein said composition has a pH from about 2.5 to about 4, and is absent of thickeners.
  • R 1 is an alkyl of 1 to 6 carbon atoms
  • m is from about 2 to about 3
  • n is from about 1 to about 2
  • said composition has a pH from about 2.5 to about 4, and is absent of thickeners.
  • the composition of the present invention provides an aqueous topical composition without thickener which is useful for lightening of mammalian skin.
  • the composition enhances the penetration of kojic acid to mammalian skin.
  • the composition has excellent lightening effect for mammalian skin, yet requires lower levels of kojic acid than previously believed necessary.
  • the reduced level of kojic acid results in a significant cost savings.
  • composition of the present invention comprises a safe and effective amount of kojic acid.
  • Kojic acid which is 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one is a well known active component and is described in the Merck Index, eleventh edition, page 838 (1989).
  • the structure of kojic acid is as follows:
  • Kojic acid is used as a skin lightening ingredient to inhibit formation of melanin. If the composition comprises more than about 3% by weight of the composition, of kojic acid, it is not economical, and if it comprises less than about 0.5% by weight of the composition, of kojic acid, enough skin lightening effect is not expected. Typically, the composition of the present invention comprises from about 0.5% to about 3%, preferably from about 1% to about 2% by weight of the composition, of kojic acid.
  • SALICYLIC ACID SALICYLIC ACID
  • composition of the present invention comprises a safe and effective amount of salicylic acid.
  • Salicylic acid which is 2-hydroxybenzoic acid is a well known active component and is described in the Merck Index, eleventh edition, page 1324 (1989).
  • T e structure of salicylic acid is as follows:
  • Salicylic acid is used to exfoliate mammalian skin and to enhance penetration of kojic acid to mammalian skin. If the composition comprises more than about 2% by weight of the composition, of salicylic acid, it will cause irritation, and if it comprises less than about 1% by weight of the composition, of salicylic acid, enough exfoliation effect and enough penetration enhancing effect is not expected. Typically, the composition of the present invention comprises from about 1% to about 2%, preferably from about 1.2% to about 1.5% by weight of the composition, of salicylic acid.
  • C. WATER T e composition of the present invention comprises water. Water is used as a solvent.
  • composition comprises more than 78.5% by weight of the composition, of water, other ingredients which are required in the present invention cannot be included, and if the composition comprises less than 40% by weight of the composition, of water, it is not economical.
  • the composition of the present invention comprises from about 40% to about 78.5%, preferably from about 45% to about 70% by weight of the composition, of water.
  • the composition of the present invention comprises water soluble glycol ether.
  • Water soluble glycol ether can be characterized by the general formula: Rl-0-[(CH2)mO]nH; wherein R is an alkyl of 1 to 6 carbon atoms, m is from about 2 to about 3, and n is from about 1 to about 2.
  • R* include methyl, ethyl, propyl, butyl and hexyl groups.
  • This glycol ether having a diethylene group as the alkylene group and ethyl group as the alkyl moiety is diethyleneglycol monoethyl ether which has been given the CTFA (The Cosmetic, Toiletry and Fragrance Association) designation ethoxydiglycol.
  • CTFA Cosmetic, Toiletry and Fragrance Association
  • Preferred water soluble glycol ether are diethyleneglycol monoethyl ether which is commercially available by the tradename TRANSCUTOL from Gattefosse, France; diethyleneglycol monomethyl ether; and dipropyleneglycol monomethyl ether and the more preferred water soluble glycol ether is diethyleneglycol monoethyl ether.
  • Water soluble glycol ether is used as a solvent of salicylic acid and to aid enhancing penetration of kojic acid to mammalian skin. If the composition comprises more than about
  • aqueous topical composition of the present invention can optionally comprise one or more components which are commonly used in such topical compositions. Examples of such optional components are discussed in more detail below.
  • thickeners not be present in the composition because it decreases the penetration effect of kojic acid to mammalian skin.
  • Thickeners means ingredients which are commonly used to increase the viscosity of cosmetics.
  • the thickeners include natural, semi-synthetic and synthetic types. Natural thickeners include gum arabic, traganth, carrageenan, xanthan gum, gelatin and sodium chondroitin sulfate.
  • Semi-synthetic thickeners include methyl cellulose, carboxymethyl cellulose, sodium nitro cellulose, ethyl cellulose, hydroxy ethyl cellulose, hydroxy methyl cellulose, hydroxy propyl cellulose, rice starch, wheat starch, sodium alginate and propylene glycol alginate.
  • Synthetic thickeners include polyvinyl alcohol, polyvinyl pyrrolidone, poly (vinyl acetate), sodium polyacrylate, polyacrylic resin, alkanolamine solution, poly (ethyl methacrylate), carboxyvinyl polymer, poly(ethylene glycol) and copolymer of polyoxyethylene and polyoxypropylene.
  • the composition preferably have a pH from about 2.5 to about 4, preferably a pH from about 3 to about 4. If pH is more than 4, preferred exfoliation effect of salicylic acid and preferred skin lightening effect of kojic acid cannot be expected, and if pH is less than 2.5, it will cause skin damage.
  • Polyhydric alcohol is used as a moisturizer. If the composition comprises more than about 15% of polyhydric alcohol, it is not economical, and causes safety issues, and if it comprises less than about 2%, the moisturizing effect is not expected.
  • Compositions of this invention can optionally comprise from about 2% to about 15%, preferably from about 3% to about 10% by weight of the composition, of polyhydric alcohols such as propylene glycol, hexylene glycol, glycerin, and propane diol. Among the polyhydric alcohol, glycerin is preferred.
  • Lower alcohols having 1 to 3 carbons can be used to impart a refreshing feel or cool sensation to the skin. If the composition comprises more than about 15% of the lower alcohols, it will cause irritation, and if the composition comprises less than about 2% of the lower alcohols, the refreshing feel and cool sensation effect is not expected.
  • compositions of this invention can optionally comprise from about 2% to about 15%, preferably from about 3% to about 10% by weight of the composition, of lower alcohols having 1 to 3 carbons such as ethanol and isopropanol Among the lower alcohols having 1 to 3 carbons, ethanol is preferred.
  • Ethanol is preferably comprised upon making compositions which are designed to impart a refreshing feel or cool sensation to the skin. It is known that ethanol in the composition helps improve solubility of salicylic acid. This level of ethanol is expected to provide the desired refreshing feel to skin without being irritating or excessively drying to the skin. 2.
  • Nonionic surfactant is preferably comprised upon making compositions which are designed to impart a refreshing feel or cool sensation to the skin. It is known that ethanol in the composition helps improve solubility of salicylic acid. This level of ethanol is expected to provide the desired refreshing feel to skin without being irritating or excessively drying to the skin.
  • Nonionic surfactant is used to aid dissolving other ingredients. If the composition comprises more than about 5% of nonionic surfactant, it is not economical and may cause safety issues, and if it comprises less than about 1% of nonionic surfactant, the effect to aid dissolving other ingredients is not expected.
  • Compositions of this invention can optionally comprise from about 1% to about 5%, preferably from about 2% to about 4% by weight of the composition, of a nonionic surfactant.
  • Nonionic surfactant acts as a co-solubilizer of salicylic acid, thereby allowing higher salicylic acid level when using the same solvent.
  • Nonionic surfactants useful herein include any of the well-known nonionic surfactants that have an HLB (hydrophile-lipophile balance) from about 10 to about 18, preferably from about 12 to 16.
  • Non-limiting examples of these nonionic surfactants are ethoxylated or propoxylated, preferably ethoxylated, alcohols and alkyl phenols with alcohol derivatives preferred.
  • these alcohol derivatives contain a straight or branched chain alkyl group having 8-22 carbons, preferably 10-20 carbons, more preferably 12-20 carbons, and generally contain from about 6 to about 30, preferably from about 8 to about 25, ethylene oxide or propylene oxide groups.
  • the ethoxylated derivatives are preferred.
  • Dialkylpolvsiloxane-polvoxyalkylene copolvmer Compositions of this invention can optionally comprise a dialkylpolysiloxane- polyoxyalkylene copolymer. Such a copolymer is expected to improve the overall skin feel imparted by the composition and to reduce any irritation which might be caused by a component of the present invention. If the composition comprises more than about 5% of dialkylpolysiloxane-polyoxyalkylene copolymer, it is not economical and may cause safety issues, and if it comprises less than about 1% of dialkylpolysiloxane-polyoxyalkylene copolymer, the effect of improving overall skin is not expected.
  • the composition preferably comprises from about 1% to about 5% of dialkylpolysiloxane - polyoxyalkylene copolymer, most preferably from about 2% to about 4% dialkylpolysiloxane - polyoxyalkylene copolymer.
  • Dialkylpolysiloxane - polyoxyalkylene copolymers useful herein include those which are soluble in water. Dimethylpolysiloxane-polyoxyalkylene copolymers, known as Dimethicone copolyols where the polyoxyalkylene group can be a polyoxyethylene or a polyoxypropylene group or a combination of both, are particularly useful.
  • the dimethylpolysiloxane portion is typically made of from 10 to about 30 units, preferably around 15 to 20 units.
  • the polyalkylene portion is typically made of from 8 to about 12, preferably from 10 to about 12 units. 4. Sunscreens, conditioning agents, vitamins, perfumes, etc.
  • optional components can be included in the aqueous topical compositions of the present invention, depending on the needs of the product.
  • optional components include water-soluble additional surfactants to aid solubility of the composition, water-soluble ultraviolet and infrared screening and absorbing agents to screen and absorb ultraviolet and infrared, water-soluble anti-inflammatory agents to reduce inflammation, water-soluble anti-oxidant radical scavenging agents to control oxidation and scavenge radical, water-soluble chelating agents to chelate metal, water-soluble skin conditioning agents to condition skin, water-soluble perfume for preference, water-soluble color for preference, water-soluble pH adjusters for adjusting pH, water-soluble dyes for preference, water-soluble vitamins to condition skin, water-soluble proteins to condition skin, water-soluble plant extracts to condition skin, and water-soluble nutrients to condition skin.
  • a composition of the present invention can include at least one anti-colouring agent selected from the group consisting of sodium metabisulfite, sodium bisulfite and sodium sulfite.
  • a wide variety of acids, bases, buffers, and sequestrants can be utilized to adjust and or maintain the pH and ionic strength of the compositions useful in the present invention.
  • Materials useful for adjusting and/or maintaining the pH and/or the ionic strength include sodium carbonate, sodium hydroxide, hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, sodium acetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, citric acid, sodium citrate, sodium bicarbonate, triethanolamine, EDTA (ethylenediaminetetraacetic acid), disodium EDTA, tetrasodium EDTA, and the like.
  • compositions of the present invention are typically formulated to have a pH from about 2.5 to about 4, preferably a pH from about 3 to about 4.
  • aqueous topical compositions of the present invention include lotions, toners and astringents.
  • the present invention also relates to methods for skin lightening in mammals comprising topical application of the skin lightening composition of the present invention.
  • the amount of active agent and frequency of application will vary widely depending upon the skin color already in existence in the subject, the rate of further darkening of the skin, and the level of lightening desired.
  • a safe and effective amount of skin lightening agent in a topical composition is applied, generally from about 1 mg to about 10 mg per cm ⁇ skin per application, preferably from about 2 mg to about 8 mg/ cm ⁇ skin per application, more preferably from about 3 mg to about 7 mg/cm ⁇ skin, also preferably from about 4 mg to about 5 mg/cm ⁇ skin.
  • Application preferably ranges from about four times a day to about twice a week, more preferably from about three times a day to about once every other day, more preferably still from about once daily to about twice daily.
  • Application for at least five days is required to see a skin lightening effect in lower animals.
  • Application for at least one month is required to see an effect in humans.
  • the frequency and dosage can be reduced to a maintenance level, as desired.
  • maintenance varies according to the individual, but is preferably from about 1/10 to about 1/2, more preferably from about 1/5 to about 1/3 of the original dosage and/or frequency, as needed.
  • TRANSCUTOL is diethyleneglycol monoethyl ether which is commercially available from
  • compositions shown in Table 1 can be prepared by any conventional method well known in the art.
  • An example of a suitable preparing method which may be used is described as follows:
  • Salicylic acid and TRANSCUTOL are combined and heated to about 70-75 °C.
  • glycerin, sodium citrate, citric acid and water are mixed together to obtain water phase-I.
  • Water phase-I is also mixed at about 70-75 °C.
  • the salicylic acid/TRANSCUTOL mixture is then slowly added to water phase-I and mixed at 75 °C for 30 minutes to obtain mixture- 1.
  • Kojic acid, sodium metabisulfite and water are mixed together to obtain water phase-II.
  • Water phase-U is also mixed at 45 °C.
  • water phase-H and D&C yellow #10 are also added to mixture- 1 to obtain a lotion.
  • Salicylic acid and TRANSCUTOL are combined and heated to about 70-75 °C.
  • water phase-I sodium citrate, citric acid, Isoceteth 20 and water are mixed together to obtain water phase-I.
  • Water phase-I is also mixed at about 70-75 °C.
  • the salicylic acid TRANSCUTOL mixture is then slowly added to water phase-I and mixed at 75 °C for 30 minutes to obtain a lotion.
  • Salicylic acid and TRANSCUTOL are combined and heated to about 70-75 °C.
  • glycerin, sodium citrate, citric acid, Isocetech 20 and water are mixed together to obtain water phase-I.
  • Water phase-I is also mixed at about 70-75 °C.
  • the salicylic acid/TRANSCUTOL mixture is then slowly added to water phase-I and mixed at 75 °C for 30 minutes to obtain mixture- 1.
  • Kojic acid, sodium metabisulfite, dimethicone copolyol and water are mixed together to obtain water phase-II.
  • Water phase-II is also mixed at 45 °C.
  • water phase-II and D&C yellow #10 are also added to mixture- 1 to obtain a lotion.
  • Preparing method of Example No. 4 Salicylic acid and TRANSCUTOL are combined and heated to about 70-75 °C.
  • water phase-I glycerin, sodium citrate, citric acid, Isoceteth 20 and water are mixed together to obtain water phase-I.
  • Water phase-I is also mixed at about 70-75 °C.
  • the salicylic acid/TRANSCUTOL mixture is then slowly added to the water phase-I and mixed at 75 °C for 30 minutes to obtain mixture-1.
  • Kojic acid, sodium metabisulfite, dimethicone copolyol and water are mixed together to obtain water phase-II.
  • Water phase-II is also mixed at 45 °C. Then water phase-II is also added to mixture-1 to obtain a lotion.
  • compositions of the present invention have improved skin penetration enhancing effect of kojic acid compared versus compositions which comprise thickener and/or comprise more than about 30% by weight of the composition, of water soluble glycol ether.
  • a strong lightening effect of mammalian skin will be obtained by the compositions of the present invention, due to the resulting strong skin penetration enhancing effect of kojic acid.
  • Example No. 5 This example sets forth a method for lightening mammalian skin using a composition of the present invention.
  • the composition of example No. 1 is applied 5 mg / cm ⁇ skin per application three times a day for one month. After one month, a significant skin lightening effect is seen. Once the desired level of the skin lightening is achieved, treatment is reduced to limit a day, to maintain the level of lightening.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention a trait à une composition aqueuse topique destinée à éclaircir la peau. Elle se compose de: (a) une quantité inoffensive et effective d'acide kojique, (b) une quantité inoffensive et effective d'acide salicylique, (c) d'eau, et (d) d'environ 20 % à 30 % en poids de la composition d'éther glycolique hydrosoluble dont la formule générale est: R1-O-[(CH¿2?)mO]nH; R?1¿ est un alkyle ayant entre 1 et 6 atomes de carbone, m est compris entre 2 et 3, et n est compris entre 1 et 2 environ; cette composition a un pH compris entre 2,5 et 4 environ, et ne contient pas d'épaississant. L'invention concerne également un procédé d'éclaircissement de la peau des mammifères qui consiste en une application topique de ladite composition aqueuse.
EP96937713A 1996-10-23 1996-10-23 Compositions topiques aqueuses a base d'acide kojique, d'acide salicylique et d'ether glycolique hydrosoluble Withdrawn EP0939616A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/016942 WO1998017247A1 (fr) 1996-10-23 1996-10-23 Compositions topiques aqueuses a base d'acide kojique, d'acide salicylique et d'ether glycolique hydrosoluble

Publications (1)

Publication Number Publication Date
EP0939616A1 true EP0939616A1 (fr) 1999-09-08

Family

ID=22256005

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96937713A Withdrawn EP0939616A1 (fr) 1996-10-23 1996-10-23 Compositions topiques aqueuses a base d'acide kojique, d'acide salicylique et d'ether glycolique hydrosoluble

Country Status (8)

Country Link
EP (1) EP0939616A1 (fr)
JP (1) JPH11510820A (fr)
KR (1) KR20000052690A (fr)
AU (1) AU7518796A (fr)
BR (1) BR9612753A (fr)
CA (1) CA2269290A1 (fr)
CZ (1) CZ141499A3 (fr)
WO (1) WO1998017247A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006100A1 (fr) * 1998-07-30 2000-02-10 The Procter & Gamble Company Produit pour le soin des cheveux conferant un aspect brillant
CA2345079C (fr) 1998-09-23 2011-06-21 Research Development Foundation Tocopherols, tocotrienols, autres derives de chromane et de chaines laterales et leurs utilisations
US7128903B2 (en) 2001-10-03 2006-10-31 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
FR2866563B1 (fr) * 2004-02-19 2008-01-11 Oreal Composition de peeling comprenant de l'acide 8-hexadecene- 1,16 dicarboxylique
KR20090004980A (ko) * 2006-04-18 2009-01-12 디에스엠 아이피 어셋츠 비.브이. 살리실산 및 아스코브산을 포함하는 화장품 조성물
LT3290043T (lt) 2015-06-01 2023-04-11 Saisei Pharma Co., Ltd. Fermentu apdorotas pieno produktas, jo gamybos būdas, kompozicija ir produktas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59157009A (ja) * 1983-02-25 1984-09-06 Yakurigaku Chuo Kenkyusho:Kk メラニン生成抑制外用剤
JP2974146B2 (ja) * 1989-01-28 1999-11-08 三省製薬株式会社 メラニン生成抑制外用剤
FR2714596B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
FR2714601B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition dépigmentante pour le traitement simultané des couches superficielles et profondes, son utilisation.
FR2719475B1 (fr) * 1994-05-05 1996-06-07 Oreal Composition cosmétique et/ou dermatologique à gélifiant polymérique cationique, ses utilisations notamment pour la dépigmentation de la peau.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9817247A1 *

Also Published As

Publication number Publication date
BR9612753A (pt) 1999-10-19
WO1998017247A1 (fr) 1998-04-30
AU7518796A (en) 1998-05-15
CZ141499A3 (cs) 1999-11-17
KR20000052690A (ko) 2000-08-25
CA2269290A1 (fr) 1998-04-30
JPH11510820A (ja) 1999-09-21

Similar Documents

Publication Publication Date Title
US5549888A (en) Aqueous topical anti-acne compositions of low pH
US5980904A (en) Skin whitening composition containing bearberry extract and a reducing agent
US5691380A (en) Stable n-acetylcysteine compositions and methods for treating human skin therewith
EP0875241B1 (fr) Composition cosmétique aqueuse, comprenant de l'acide urique solubilisée stable et un polymère hydrosoluble, et procédé de solubiliser l'acide urique de manière stable dans une composition cosmétique aqueuse
WO1997015283A1 (fr) Compositions topiques contenant de la n-acetylcysteine et des substances masquant les odeurs
CA2526626A1 (fr) Base d'emulsion pour compositions de soins de la peau
US6436378B1 (en) Composition
US6468552B1 (en) Stabilized compositions containing oxygen-labile active agents
EP0939616A1 (fr) Compositions topiques aqueuses a base d'acide kojique, d'acide salicylique et d'ether glycolique hydrosoluble
CA2497206C (fr) Preparations epaississantes comprenant de la gomme de sclerote et un copolymere
WO2012068444A2 (fr) Compositions contenant des taux faibles de colorant pour améliorer l'aspect de la peau
JP3495446B2 (ja) 毛髪化粧料
AU7733401A (en) Method for promoting clear skin
JP3441785B2 (ja) 染毛剤組成物
US20010053350A1 (en) Cosmetic composition comprising N-ethyloxycarbonyl-4-amino-phenol and arbutin or its derivatives and/or ellagic acid or its derivatives
MXPA99003846A (en) Aqueous topical compositions comprising kojic acid, salicylic acid and a water soluble glycol ether
US6063389A (en) Composition for depigmenting or bleaching mammalian skin containing L-2-oxothiazolidine-4-carboxylic acid and a polyol
US6960347B2 (en) Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives
AU2002250193B2 (en) Skin composition
JP2002145742A (ja) 養毛料
CN1234734A (zh) 含有曲酸、水杨酸和水溶性二醇醚的含水局部用组合物
JPH1135428A (ja) 白髪防止用組成物
JPH11106318A (ja) 頭部用組成物
AU2002250193A1 (en) Skin composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000911

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020502